AstraZeneca shares fall 7% after cancer drug Gefitinib plea shot down

AstraZeneca

Shares of AstraZeneca Pharma today tumbled over 7 per cent, after the Intellectual Property Appellate Board (IPAB) turned down the drug firm's plea for a patent on the lung cancer drug Gefitinib.

Following the move, shares of the company opened weak and as the trade progressed it tanked 7.38 per cent to Rs 1,449.50 on the BSE.

At NSE, the scrip slipped 7.65 per cent to Rs 1,444.05.

Reacting on the development, the company said it is disappointed and is evaluating its options.

"We are disappointed by the Intellectual Property Appellate Board's decision.

We are confident in the validity of the claims in this patent application and are now evaluating our next steps," AstraZeneca said in a statement.

IPAB on November 26 upheld its earlier decision to refuse AstraZeneca a patent claim in 2007, citing lack of invention.

Decline in the stock was in contrast with a robust stock market where the benchmark index Sensex was trading at 19,093.42, up 251.34 points.

Please read our terms of use before posting comments
TERMS OF USE: The views expressed in comments published on indianexpress.com are those of the comment writer's alone. They do not represent the views or opinions of The Indian Express Group or its staff. Comments are automatically posted live; however, indianexpress.com reserves the right to take it down at any time. We also reserve the right not to publish comments that are abusive, obscene, inflammatory, derogatory or defamatory.